Stryker Q3 underperformance driven by orthopedic volume weakness

Mar Vista Investment Partners, LLC cited a loss of investor confidence in Stryker Corporation's near-term growth trajectory as the primary driver behind the company's underperformance during the third quarter of 2026. The firm noted that this sentiment did not reflect a deterioration in the long-term franchise of the medical technology company, which operates across MedSurg, Neurotechnology, and Orthopaedics segments.

Stryker Corporation closed at $276.97 on October 8, 2026, establishing a market capitalization of $106.24 billion. The stock recorded a year-to-date pullback of approximately 21.20%, trading within a 52-week range that spanned from $267.00 to $392.55. Trailing twelve-month revenue for the company stood at $25.84 billion. Mar Vista's U.S. Quality Strategy posted a net return of +1.45% for the quarter, trailing the Russell 1000 Index return of +1.79% and the S&P 500 Index return of +2.30%. Healthcare was identified as a detractor to the strategy's performance, while information technology, consumer discretionary, and financials contributed positively.

Management had anticipated that U.S. orthopedic procedure growth would accelerate following a strong June, but data from July and August indicated normal seasonality accompanied by hip and knee volumes that fell below expectations. The company attributed these results to longer procedure lead times and anecdotal patient deferrals linked to inflation and out-of-pocket costs. These macroeconomic pressures were compounded by specific operational challenges, including continued weakness in European hip sales and a competitive gap stemming from the absence of a hip impactor product.

A manufacturing and supply issue within the Peripheral Vascular division, which management had projected would resolve in the third quarter, was reported to extend into the fourth quarter. Additionally, a cyberattack in March disrupted order processing, manufacturing, and shipping operations, forcing some procedures to be rescheduled and adding noise to quarterly comparisons. Hedge fund interest in Stryker Corporation declined during the period, with 72 portfolios holding the stock at the end of the second quarter, down from 81 in the previous quarter. Mar Vista stated that certain artificial intelligence stocks currently offer greater upside potential and less downside risk compared to Stryker.